Current Guidelines for Hepatitis B Treatment
Pegasys (peginterferon alfa-2a) is no longer considered a first-line treatment for chronic hepatitis B (CHB) in major guidelines. The American Association for the Study of Liver Diseases (AASLD) 2018 update recommends nucleos(t)ide analogs like entecavir or tenofovir as preferred first-line options due to higher efficacy, better tolerability, and oral administration.[1] European Association for the Study of the Liver (EASL) 2017 guidelines similarly prioritize entecavir and tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) for most patients.[2]
When Is Pegasys Still Used?
Guidelines reserve peginterferon for select cases, such as:
- HBeAg-positive young patients (<40 years) with low viral load and high ALT, where finite treatment (48 weeks) offers a chance for HBsAg seroclearance.
- Genotype A infections in HBeAg-positive patients, due to better response rates.
It's not recommended for HBeAg-negative CHB, decompensated cirrhosis, or patients over 65, given lower sustained response rates (20-30% vs. >90% virologic suppression with nucleos(t)ides).[1][2]
Why the Shift Away from Interferon?
Peginterferon has an unfavorable profile: subcutaneous injections, flu-like side effects, cytopenias, and psychiatric risks lead to high discontinuation (up to 30%). Long-term data show nucleos(t)ides achieve better viral suppression and lower resistance, though they require indefinite therapy without curing most cases.[3] Real-world studies confirm entecavir/tenofovir as dominant first-line choices.
Upcoming Changes and Alternatives
Newer agents like RNA interference therapies (e.g., siRNA) are in late-stage trials, potentially offering functional cures, but nucleos(t)ides remain standard.[4] Pegasys patent expired in 2020 in the US; generics exist, but usage has declined.[5]
Sources
[1]: AASLD Hepatitis B Guidance
[2]: EASL 2017 Clinical Practice Guidelines
[3]: Terrault et al., Hepatology 2018
[4]: FDA pipeline updates
[5]: DrugPatentWatch - Pegasys